Silencing of CDC6 has been found to restore sensitivity to oxaliplatin in HuR overexpressing cells by reducing drug resistance hallmarks such as cancer cell migration, invasion, and EMT (Cai et al., 2019). The gene discussed is ELAVL1; the disease is cancer.